Stocks To Buy Now

Blog

The Stocks To Buy Now Blog

Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.

If you’re looking for market insight, undervalued gems, and an assortment of investment options, read on.

Nutra Pharma Corp. (NPHC) Applies for Additional Orphan Drug Designation for RPI-78M

Nutra Pharma Corp., a biotechnology company marketing Nyloxin® and Pet Pain-Away in the over-the-counter (OTC) pain management market, as well as developing treatments for multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN) and pain, announced today that it has applied for an Orphan Drug designation from the U.S.-FDA for the Company’s RPI-78M drug candidate […]

International Stem Cell Corp. (ISCO) Has a Broad Pipeline of Targets

International Stem Cell Corp. is tackling some of the world’s most debilitating health maladies with a powerful new stem cell technology that employs parthenogenesis. Parthenogenesis is a type of reproduction that takes place in the absence of fertilization. The company’s new stem cell technology holds the promise of advancing significantly the field of regenerative medicine […]

 

From Our Blog

Soligenix Inc. (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status

April 17, 2026

Recognition from global regulatory authorities can serve as a powerful validation of a therapy’s potential, particularly in the rare disease space where development challenges are significant and patient needs are urgent. Soligenix (NASDAQ: SNGX) has secured that type of validation, as the European Commission granted orphan drug designation to its investigational therapy SGX945 for the […]

Rotate your device 90° to view site.